Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
UBS raises price target for Brenntag to 61 euros, rating remains neutral
UBS analyst Nicole Manion has raised Brenntag’s price target from 60 to 61 euros but kept the rating at neutral. Inflationary chemical prices and supply-chain disruptions from the Middle East conflict have helped in the short term, yet upside is limited as the price boost is expected to fade in the second half of the year. Brenntag shares are up 27.5 percent year-to-date 2026; Q3 figures are expected on November 11, 2026. » Plus sur finanzen.net
Brenntag: Goldman raises target price to €76, stock falls despite strong Q2 figures
Goldman Sachs has raised its target price for Brenntag to €76 and kept its rating at "Buy", but the stock still fell about 3.1% to €59.76. In the second quarter, revenue and net profit rose significantly and management raised the full-year guidance. However, analyst consensus remains cautious (average target €57.43) and investors question whether the profit jump is sustainable. Strategically, Brenntag is shifting its business toward higher‑margin speciality chemicals via "Project Brenntag" and the acquisition of MCE Pharma; the Q3 report on November 11 is viewed as the next test. » Plus sur de.investing.com
Brenntag confirms full-year EBITDA despite strong Q2, shares slightly down
Brenntag reported Q2 EBITDA of €463m and H1 EBITDA of €770m and confirmed its full-year guidance of €1.45bn. Results were supported by higher prices following supply disruptions in the Middle East, while volumes remained stable. The cost-reduction program is progressing faster than planned (run-rate €41m), but working capital saw a temporary outflow of €353m. Investors cited the prospect of a weaker second half as the reason for a moderate share price decline. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 4,26Md | 10,17% |
| Bénéfice brut | 613,00M | 37,08% |
| Bénéfice net | 179,00M | 317,25% |
| EBITDA | 418,00M | 31,70% |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 8,73Md€ |
Nombre d'actions | 144,39M |
Plus haut/bas sur 52 semaines | 66,86€ - 43,72€ |
Rendement du dividende | 3,14% |
Dividendes TTM | 1,90€ |
Bêta | 0,53 |
Ratio P/E | 23,98 |
Ratio PEG | −1,71 |
Ratio P/B | 1,96 |
Ratio P/S | 0,58 |
Profil de l'entreprise
Die Brenntag SE kauft und liefert verschiedene Industrie- und Spezialchemikalien sowie Inhaltsstoffe in Europa, dem Nahen Osten, Afrika, Nordamerika, Lateinamerika, dem asiatisch-pazifischen Raum und international. Das Unternehmen ist in den Geschäftsbereichen Brenntag Essentials und Brenntag Specialties tätig. Das Unternehmen bietet Mehrwertdienste wie Just-in-Time-Lieferung, Produktmischung, Blending, Umpacken, Bestandsmanagement und Fassrücknahme sowie technische und Labordienstleistungen für Spezialchemikalien. Das Unternehmen beliefert Kunden aus den Bereichen Ernährung, Pharma, Körperpflege, Wasseraufbereitung und Schmierstoffe sowie aus den Bereichen Haushalt, Industrie und Institutionen, Beschichtungen und Bauwesen, Polymere und Gummi. Die Brenntag SE wurde 1874 gegründet und hat ihren Sitz in Essen, Deutschland.
| Nom | Brenntag |
| PDG | Jens Birgersson |
| Siège social | Essen,
nw Allemagne |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 29/03/2010 |
| Employés | 16.942 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
XETRA | BNR.DE |
Pnk | BNTGF |
SIX | BNR.SW |
Frankfurt | BNR.F |
Düsseldorf | BNR.DU |
Hamburg | BNR.HM |
Milan | 1BRE.MI |
London | 0MPT.L |
München | BNR.MU |
Wien | BNR.VI |
Découvrir des actifs
Les actionnaires de Brenntag investissent également dans les actifs suivants
